

# An Introduction to CTIP & Pediatric Innovation



Juan Espinoza, MD

Executive Director and Principal Investigator

Consortium for Technology & Innovation in Pediatrics (CTIP)





# Current State of Pediatric Medical Devices (PMD)

- The availability and sophistication of PMDs lags behind adult devices by as much as <u>10 years</u>
- Children experience innovation <u>differently</u> than adults
- PMD innovation represents a significant <u>health inequity</u>, with the majority of device development targeting adult populations
- This gap is greatest for young children, and for high-risk, life saving devices





# Current State of Pediatric Medical Devices (PMD)

- Most pediatric use of devices is off-label, with little or no safety data
- Children are exposed to inconsistent benefit-risk profiles from the necessary off-label use of devices.
- Devices designed, evaluated, and labelled for children improve safety profiles and health equity.



- Scientific and engineering challenges
- Ethical challenges
- Regulatory challenges
- Financial challenges












- Scientific and engineering challenges
- Ethical challenges
- Regulatory challenges
- Financial challenges













- Children (under 21) represent ~25% of the US population
- <10% of US Healthcare dollars are spent in pediatrics
- Pediatric care is reimbursed at <u>50-70%</u> of the same or comparable service for adults
- There are <u>almost no national coverage policies</u> for pediatric healthcare






- Other areas are equally underinvested
  - Research: 12% of the NIH budget is pediatric research
  - <u>Investors:</u> 1% 4% of health tech deals are related to pediatrics (if you include digital health)





- Medical devices are expensive to develop (\$30 million to \$200 million)
- Long journey to market (3 to 10 years)
- Pediatric market can be heterogenous & unpredictable in terms of revenue generation





# How Do We Turn This Around?








# Opportunities to Advance PMDs

- We can change the shape of the curve
  - More public funding
  - Incentives for private funding
  - Reduce the cost of the valley of death
  - Shorten the time in the valley of death
  - Increase revenue generation opportunities





# Opportunities to Advance PMDs

- Regulatory and legislative innovation
- Increase research funding
- Robust and reliable value generation mechanisms
- Real world evidence
- Industry support
- Pediatric Device Consortia
- PMD-PPP

















### The Pediatric Device Consortia



Pediatric Device Consortia Grants Program





### The Pediatric Device Consortia

#### 2009

The Michigan Pediatric Device Consortium (A)

University of California, San Francisco Pediatric Device Consortium (B)

The MISTRAL Device Consortium (C)

The Pediatric Cardiovascular Device Consortium (**D**)

#### 2011

University of Michigan MPED & PMDI Pediatric Medical Device Consortium (A)

University of California, San Francisco Pediatric Device Consortium (B)

Atlanta Pediatric Device Consortium (E)

#### 2013

University of Michigan Pediatric Device Consortium (A)

Boston Pediatric Device Consortium (D)

Atlantic Pediatric Device Consortium (E)

National Capital Consortium for Pediatric Device Innovation (F)

New England Pediatric Device Consortium
(G)

Southern California Center for Technology and Innovation in Pediatrics (H)

Philadelphia Regional Pediatric Medical Device Consortium (I)

#### 2018


UCSF-Stanford Pediatric Device Consortium (B+C)

National Capital Consortium for Pediatric Device Innovation 2.0 (F)

The West Coast Consortium for Technology & Innovation in Pediatrics (H)

Pennsylvania Pediatric Medical Device Consortium (I)

Southwest National Pediatric Device Innovation Consortium (J)



- 14 years
- 4 grant cycles
- 20 awards
- 10 institutions



### The 2023-2028 PDCs








- CTIP established at CHLA+USC
- CTIP first funded by FDA
- \$2.2M Fund I
- Southern California focus
- CTIP refunded by FDA
- \$6.6M Fund II
- Expands across the West Coast: California, Oregon, and Washington
- CTIP moved to Lurie
- CTIP refunded by FDA
- \$5.8M Fund III
- Expands to 26 organizations across 8 states




- Our goal is to advance pediatric medical devices along the path from concept to commercialization
- We work with innovators and entrepreneurs at any stage (concept, prototype, etc.)
- CTIP does NOT take any stake, IP, or ownership













#### **Portfolio Metrics**

#### **500+** Projects Evaluated

#### **146** Portfolio Members

<b>Anticipated Device Cl</b>	ass
Class I	32 (22%)
Class II	84 (58%)
510k	62 (43%)
De Novo	16 (11%)
Exempt	6 (4%)
Class III	10 (7%)
Combination Product	3 (2%)
To be determined	15 (10%)
Intended Pediatric Su	bpopulatio
Neonates	61 (42%)
Infants	76 (53%)
Children	107 (74%)
Adolescents	105 (73%)





7 Granted

In review

**STeP Program** 

2 In progress

3 Granted

### **Diverse & Inclusive Portfolio**

Out of 108 Portfolio Members self-reporting their identity, they identified as:

55% Women

6% LGBTQ+

44% URM or Person of Color

5% Veterans

Individuals with disabilities

#### **Fundraising**

#### **Total Funds Raised**

By all CTIP Portfolio Members:

\$210.2 Million Before joining CTIP

\$422.7 Million Since joining CTIP

\$632.9 Million Total raised

#### **Federal Grant Funding**

51 Grants 31 Recipients

24 SBIR Phase I \$7.9M 15 SBIR Phase II \$20.6M 7 STTR Phase I \$1.8M \$6.5M 6 Other federal grants

2 STTR Phase II \$2M

\$38.8 Million Awarded

#### **Clinical Research**

Portfolio members initiated clinical research including first-in-human, pilots, and clinical trials

**Projects supported by CTIP Medical Device Clinical Trials Unit** over a 12-month period

### Marketing & Commercialization

#### **Breakthrough Device**

**Devices on Market** 





**Technologies** licensed or acquired

### **Publications**

#### **CTIP Team**

Academic **Publications** 

**→** RWE Publications

#### **Portfolio Members**

Academic . **Publications** 

Poster Presentations

Other Presentations, Publications & Media Appearances







Juan Espinoza, MD | Executive Director Melissa Bent, MD | Co-Director Yaniv Bar-Cohen, MD | Co-Director Bianca Riello, MEng | Managing Director **Kathryne Cooper, MBA** | Investment Advisor Salima Jamal, MBA | Program Manager **Greg Zapotoczny, PhD** | Regulatory Lead & MDCTU Director Madison Christmas, BS | Program Associate, Investment & Growth Nadine Afari, MS | Program Associate, Research & Education Jordan Cashwell, MPH | Program Coordinator Rachel Spencer, BA | Communications Coordinator Tamara Lambert, PhD | CobiCure MedTech Innovation Fellow





Friday, August 15th 11am-6pm SQBRC Lobby

# Registration:



https://bit.ly/ctip2025